British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice

Reed, Nick; Balega, Janos; Barwick, Tara; Buckley, Lynn; Burton, Kevin; Eminowicz, Gemma; Forrest, Jenny; Ganesan, Raji; Harrand, Rosie; Holland, Cathrine; Howe, Tamara; Ind, Thomas; Iyer, Rema; Kaushik, Sonali; Music, Robert; Sadozye, Azmat; Shanbhag, Smruta; Siddiqui, Nadeem; Syed, Salahuddin; Percival, Natalie; Whitham, Natasha Lauren; Nordin, Andy; Fotopoulou, Christina

doi:10.1016/j.ejogrb.2020.08.020

Cited by 47 publications

(45 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the early stages, cervical cancer is often unnoticed due to the inconspicuous symptoms. However, many common symptoms such as vaginal bleeding, abnormal vaginal discharge, and dyspareunia occur when cervical cancer advances to the terminal stage ( Reed et al, 2021 ). Although the development of cervical cancer could be prevented by routine screening and other treatment approaches, mortality rates do not decrease significantly.…”

Section: Introductionmentioning

confidence: 99%

From Microbiome to Inflammation: The Key Drivers of Cervical Cancer

et al. 2021

View full text Add to dashboard Cite

Cervical cancer is the third leading cause of cancer-related death worldwide. Microbes and hosts form a mutually beneficial symbiosis relationship, and various parts of the host body are microbial habitats. Microbes can trigger inflammation in certain parts of the host body, contributing to cervical cancer development. This article reviews the relationship between cervicovaginal microbes, inflammation and cervical cancer, and discusses the effect of some key cervical microbes on cervical cancer. Finally, probiotic therapy and immunotherapy are summarized.

show abstract

Section: Introductionmentioning

confidence: 99%

From Microbiome to Inflammation: The Key Drivers of Cervical Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Stage IA1 is managed by local excision or a simple hysterectomy. Stage IA2eIB2 disease is managed by radical hysterectomy (standard hysterectomy plus removal of paracervical tissue and upper third of vagina) plus bilateral pelvic lymphadenectomy [106]. Many women with small tumours (<2 cm) can be spared radical surgery [107,108], and the ongoing SHAPE and GOG 278 trials seek to evaluate the role of more conservative surgery in early stage disease.…”

Section: Surgical Treatmentmentioning

confidence: 99%

Eliminating Cervical Cancer: Progress and Challenges for High-income Countries

Davies-Oliveira¹,

Smith²,

Grover³

et al. 2021

Clinical Oncology

View full text Add to dashboard Cite

In 2020, the World Health Organization launched a major initiative to eliminate cervical cancer globally. The initiative is built around the three key pillars of human papillomavirus (HPV) vaccination, cervical screening and treatment, with associated intervention targets for the year 2030. The '90-70-90' targets specify that 90% of adolescent girls receive prophylactic HPV vaccination, 70% of adult women receive a minimum twice-in-a-lifetime cervical HPV test and 90% receive appropriate treatment for preinvasive or invasive disease. Modelling has shown that if these targets are met, the elimination of cervical cancer, defined as fewer than four cases per 100 000 women per annum, will be achieved within a century. Many high-income countries are well positioned to eliminate cervical cancer within the coming decades, but few have achieved '90-70-90' and many challenges must still be addressed to deliver these critical interventions effectively. This review considers the current status of cervical cancer control in relation to each of the three elimination pillars in high-income countries and discusses some of the developments that will assist countries in reaching these ambitious targets by 2030.

show abstract

“…Women need to be counselled regarding the limited evidence currently available on the long-term safety of sentinel lymph node biopsy alone compared with full lymphadenectomy. To acquire this evidence and support the use of sentinel lymph node biopsy in cervical cancer, recruitment to prospective clinical trials is encouraged [80,81]. There are currently two ongoing prospective trials exploring the oncological safety of sentinel lymph nodes in cervical cancer (SENTIX ¼ NCT02494063; SENTICOL III ¼ NCT03386734).…”

Section: Stagingmentioning

confidence: 99%

“…The National Institute for Health and Care Excellence (NICE) is yet to publish final guidance, but on a draft of the guidance, it recommends that for tumour size >2 cm an open approach should be used and for <2 cm an MIS approach should only be adopted in the context of research [103]. The British Gynaecological Cancer Society emphasises the importance of careful counselling of patients on the current evidence, discussing in detail the risks and benefits to enable an informed choice to be made [81].…”

Section: Primary Treatmentmentioning

confidence: 99%